On Friday, Akebia Therapeutics Inc (NASDAQ: AKBA) opened higher 7.25% from the last session, before settling in for the closing price of $1.93. Price fluctuations for AKBA have ranged from $0.80 to $2.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -8.86% over the past five years. Company’s average yearly earnings per share was noted -13.10% at the time writing. With a float of $207.61 million, this company’s outstanding shares have now reached $211.54 million.
Let’s look at the performance matrix of the company that is accounted for 167 employees. In terms of profitability, gross margin is 63.13%, operating margin of -20.45%, and the pretax margin is -27.07%.
Akebia Therapeutics Inc (AKBA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Akebia Therapeutics Inc is 4.85%, while institutional ownership is 24.87%. The most recent insider transaction that took place on May 13 ’24, was worth 15,140. In this transaction SVP, Chief Legal Officer of this company sold 12,016 shares at a rate of $1.26, taking the stock ownership to the 651,243 shares. Before that another transaction happened on May 13 ’24, when Company’s SVP, Chief Operating Officer sold 34,840 for $1.26, making the entire transaction worth $43,898. This insider now owns 672,092 shares in total.
Akebia Therapeutics Inc (AKBA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.10% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Check out the current performance indicators for Akebia Therapeutics Inc (AKBA). In the past quarter, the stock posted a quick ratio of 1.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.21 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Akebia Therapeutics Inc (NASDAQ: AKBA) saw its 5-day average volume 3.21 million, a positive change from its year-to-date volume of 2.5 million. As of the previous 9 days, the stock’s Stochastic %D was 83.02%. Additionally, its Average True Range was 0.10.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 89.25%, which indicates a significant decrease from 94.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.87% in the past 14 days, which was lower than the 56.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.91, while its 200-day Moving Average is $1.46. Nevertheless, the first resistance level for the watch stands at $2.13 in the near term. At $2.20, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.30. If the price goes on to break the first support level at $1.96, it is likely to go to the next support level at $1.86. The third support level lies at $1.79 if the price breaches the second support level.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
There are currently 218,181K shares outstanding in the company with a market cap of 451.64 million. Presently, the company’s annual sales total 194,620 K according to its annual income of -51,930 K. Last quarter, the company’s sales amounted to 37,430 K and its income totaled -20,040 K.
